{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:43Z","timestamp":1790419723770,"version":"4.1.0"},"reference-count":45,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,12,9]]},"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Antidepressant use during gestation has been associated with risk of major congenital malformations but estimates can lack statistical power or be confounded by maternal depression. We aimed to determine the association between first-trimester exposure to antidepressants and the risk of major congenital malformations in a cohort of depressed\/anxious women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and participants<\/jats:title>\n                    <jats:p>Data were obtained from the Quebec Pregnancy Cohort (QPC). All pregnancies with a diagnosis of depression or anxiety, or exposed to antidepressants in the 12\u2005months before pregnancy, and ending with a live-born singleton were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Antidepressant classes (selective serotonin reuptake inhibitors (SSRI), serotonin\u2013norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA) and other antidepressants) and types were individually compared with non-exposure during the first trimester (depressed untreated). Major congenital malformations overall and organ-specific malformations in the first year of life were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>18\u2005487 pregnant women were included. When looking at the specific types of antidepressant used during the first trimester, only citalopram was increasing the risk of major congenital malformations (adjusted OR, (aOR) 1.36, 95% CI 1.08 to 1.73; 88 exposed cases), although there was a trend towards increased risk for the most frequently used antidepressants. Antidepressants with serotonin reuptake inhibition effect (SSRI, SNRI, amitriptyline (the most used TCA)) increased the risk of certain organ-specific defects: paroxetine increased the risk of cardiac defects (aOR 1.45, 95% CI 1.12 to 1.88), and ventricular\/atrial septal defects (aOR 1.39, 95% CI 1.00 to 1.93); citalopram increased the risk of musculoskeletal defects (aOR 1.92, 95% CI 1.40 to 2.62), and craniosynostosis (aOR 3.95, 95% CI 2.08 to 7.52); TCA was associated with eye, ear, face and neck defects (aOR 2.45, 95% CI 1.05 to 5.72), and digestive defects (aOR 2.55, 95% CI 1.40 to 4.66); and venlafaxine was associated with respiratory defects (aOR 2.17, 95% CI 1.07 to 4.38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antidepressants with effects on serotonin reuptake during embryogenesis increased the risk of some organ-specific malformations in a cohort of pregnant women with depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013372","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T20:35:21Z","timestamp":1484253321000},"page":"e013372","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":134,"title":["Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort"],"prefix":"10.1136","volume":"7","author":[{"given":"Anick","family":"B\u00e9rard","sequence":"first","affiliation":[{"name":"Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada"},{"name":"Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada"},{"name":"Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Sheehy","sequence":"additional","affiliation":[{"name":"Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,1,12]]},"reference":[{"key":"2025121513162019000_7.1.e013372.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.01.033"},{"key":"2025121513162019000_7.1.e013372.2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818b53fd"},{"key":"2025121513162019000_7.1.e013372.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2011.09.004"},{"key":"2025121513162019000_7.1.e013372.4","doi-asserted-by":"crossref","unstructured":"Ciraulo DA , Shader RI . Pharmacotherapy of depression. 2nd edn. Springer, 2011:34.","DOI":"10.1007\/978-1-60327-435-7"},{"key":"2025121513162019000_7.1.e013372.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067407"},{"key":"2025121513162019000_7.1.e013372.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066584"},{"key":"2025121513162019000_7.1.e013372.7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CLEP.S9256","article-title":"Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis","volume":"2","author":"Kornum","year":"2010","journal-title":"Clin Epidemiol"},{"key":"2025121513162019000_7.1.e013372.8","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20099"},{"key":"2025121513162019000_7.1.e013372.9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/FTD.0b013e31826d07ea","article-title":"Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome","volume":"34","author":"Malm","year":"2012","journal-title":"Ther Drug Monit"},{"key":"2025121513162019000_7.1.e013372.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.01.034"},{"key":"2025121513162019000_7.1.e013372.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312828"},{"key":"2025121513162019000_7.1.e013372.12","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12682"},{"key":"2025121513162019000_7.1.e013372.13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/pds.3462","article-title":"Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121513162019000_7.1.e013372.14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182490eaf"},{"key":"2025121513162019000_7.1.e013372.15","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709992194"},{"key":"2025121513162019000_7.1.e013372.16","doi-asserted-by":"crossref","first-page":"e93870","DOI":"10.1371\/journal.pone.0093870","article-title":"The Quebec Pregnancy Cohort\u2014prevalence of medication use during gestation and pregnancy outcomes","volume":"9","author":"Berard","year":"2014","journal-title":"PLoS ONE"},{"key":"2025121513162019000_7.1.e013372.17","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1558"},{"key":"2025121513162019000_7.1.e013372.18","unstructured":"Briggs GG , Freeman RK , Yaffe SJ . Drugs in pregnancy and lactation. 9th edn. New York: Lippincott William & Wilkins, 2011."},{"key":"2025121513162019000_7.1.e013372.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2009.02377.x"},{"key":"2025121513162019000_7.1.e013372.20","first-page":"155","article-title":"Can we rely on pharmacy claims databases to ascertain maternal use of medications during pregnancy?","volume":"22","author":"Jobin-Gervais","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121513162019000_7.1.e013372.21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3446"},{"key":"2025121513162019000_7.1.e013372.22","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.93101s2153"},{"key":"2025121513162019000_7.1.e013372.23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.EDE.0000071419.41011.cf","article-title":"Semi-automated sensitivity analysis to assess systematic errors in observational data","volume":"14","author":"Lash","year":"2003","journal-title":"Epidemiology"},{"key":"2025121513162019000_7.1.e013372.24","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyi184"},{"key":"2025121513162019000_7.1.e013372.25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bdra.20643","article-title":"Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?","volume":"88","author":"Berard","year":"2010","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"key":"2025121513162019000_7.1.e013372.26","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420470609"},{"key":"2025121513162019000_7.1.e013372.27","first-page":"75","article-title":"Serotonin and morphogenesis. Transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse","volume":"187","author":"Shuey","year":"1993","journal-title":"Anat Embryol (Berl)"},{"key":"2025121513162019000_7.1.e013372.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdevneu.2003.10.002"},{"key":"2025121513162019000_7.1.e013372.29","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20773"},{"key":"2025121513162019000_7.1.e013372.30","doi-asserted-by":"crossref","first-page":"pii: e001148","DOI":"10.1136\/bmjopen-2012-001148","article-title":"Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study","volume":"2","author":"Jimenez-Solem","year":"2012","journal-title":"BMJ Open"},{"key":"2025121513162019000_7.1.e013372.31","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-015-0065-y"},{"key":"2025121513162019000_7.1.e013372.32","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20144"},{"key":"2025121513162019000_7.1.e013372.33","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20627"},{"key":"2025121513162019000_7.1.e013372.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1798"},{"key":"2025121513162019000_7.1.e013372.35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/bcp.12849","article-title":"The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis","volume":"81","author":"B\u00e9rard","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025121513162019000_7.1.e013372.36","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31815ac4d2"},{"key":"2025121513162019000_7.1.e013372.37","first-page":"336","article-title":"Exposure to prescribed drugs in pregnancy and association with congenital malformations","volume":"58","author":"Bracken","year":"1981","journal-title":"Obstet Gynecol"},{"key":"2025121513162019000_7.1.e013372.38","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23096"},{"key":"2025121513162019000_7.1.e013372.39","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9926(199907)60:1<33::AID-TERA9>3.0.CO;2-X"},{"key":"2025121513162019000_7.1.e013372.40","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091208"},{"key":"2025121513162019000_7.1.e013372.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)34177-9"},{"key":"2025121513162019000_7.1.e013372.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.003"},{"key":"2025121513162019000_7.1.e013372.43","first-page":"e198","article-title":"Regional variations in the prevalence of major congenital malformations in Quebec: the importance of fetal growth environment","volume":"22","author":"Zhao","year":"2015","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"2025121513162019000_7.1.e013372.44","first-page":"e360","article-title":"Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database","volume":"16","author":"Berard","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"2025121513162019000_7.1.e013372.45","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pds.3798","article-title":"Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data","volume":"24","author":"Swanson","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:16:30Z","timestamp":1765833390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,12]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/bmjopen-2016-013372"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013372","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}